These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 22096922

  • 21. Side effects of antiviral therapy in hepatitis C virus infection-sarcoidosis - case report.
    Teodor D, Teodor A, Grigore L, Jugănariu G, Dorobăţ CM, Miftode E, Azoicăi D.
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1039-43. PubMed ID: 23700885
    [Abstract] [Full Text] [Related]

  • 22. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep 19; 144(38):59. PubMed ID: 12395712
    [No Abstract] [Full Text] [Related]

  • 23. Summaries for patients. Duration and dose of antiviral treatment for chronic hepatitis C.
    Ann Intern Med; 2004 Mar 02; 140(5):I67. PubMed ID: 14996694
    [No Abstract] [Full Text] [Related]

  • 24. [Cutaneous sarcoidosis after treatment with interferon for hepatitis C: A not entirely rare but often overlooked reaction].
    Waltschew A.
    Pathologe; 2016 Mar 02; 37(2):184-6. PubMed ID: 26769217
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
    Gluhovschi C, Gadalean F, Kaycsa A, Curescu M, Sporea I, Gluhovschi G, Petrica L, Velciov S, Bozdog G, Bob F, Vernic C, Cioca D.
    Immunopharmacol Immunotoxicol; 2011 Dec 02; 33(4):744-50. PubMed ID: 21320001
    [Abstract] [Full Text] [Related]

  • 28. [Respiratory function impairment during treatment of chronic hepatitis C with peginterferon alfa2 and ribavirin. Two cases presentation].
    Biedroń-Machura M, Musialik J, Sozańska E, Zbroszczyk M, Baron J, Błońska-Fajfrowska B, Pierzchała W.
    Wiad Lek; 2012 Dec 02; 65(4):232-8. PubMed ID: 23654144
    [Abstract] [Full Text] [Related]

  • 29. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
    Mousa N, Besheer T, Gad Y, Elbendary A, Mokbel T, Abdel-Aziz A.
    J Ocul Pharmacol Ther; 2013 Apr 02; 29(3):345-8. PubMed ID: 23113644
    [Abstract] [Full Text] [Related]

  • 30. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J.
    J Viral Hepat; 2009 Mar 02; 16(3):168-77. PubMed ID: 19175874
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study [KULDS] Group.
    J Gastroenterol Hepatol; 2012 Jul 02; 27(7):1233-40. PubMed ID: 22098185
    [Abstract] [Full Text] [Related]

  • 33. [Autoimmune hemolytic anemia in a case of chronic hepatitis type C 56 weeks after initiation of second line treatment with pegylated interferon alpha2b/ribavirin combination therapy].
    Nishino R, Ikeda N, Unoura M.
    Nihon Shokakibyo Gakkai Zasshi; 2011 Sep 02; 108(9):1571-8. PubMed ID: 21891998
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Medicines for liver diseases; interferon preparations and anti-hepatitis virus agents].
    Iwasaki Y, Ikeda F, Yamamoto K.
    Nihon Rinsho; 2012 Aug 02; 70 Suppl 6():272-8. PubMed ID: 23156520
    [No Abstract] [Full Text] [Related]

  • 36. [Adverse reactions of different treatments in chronic hepatitis C].
    Luca C, Grigore L, Vâţă A, Dorobăţ C.
    Rev Med Chir Soc Med Nat Iasi; 2009 Aug 02; 113(4):991-5. PubMed ID: 20191864
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, Tsai MC, Lin MT, Lee CT, Shen CH, Hu TH.
    Am J Kidney Dis; 2013 Oct 02; 62(4):789-95. PubMed ID: 23746377
    [Abstract] [Full Text] [Related]

  • 38. Treatment of chronic hepatitis C in children with pegylated interferon α2a and ribavirin--a multi-center study.
    Słuzewski W, Kowala-Piaskowska A, Wysocki J, Figlerowicz M, Gorczyca A, Halota W, Jóźwiak H, Mizerski J, Mozer-Lisewska I, Pawłowska M, Rokitka M, Strawińska E, Szamotulska K.
    Acta Pol Pharm; 2012 Oct 02; 69(2):319-26. PubMed ID: 22568047
    [Abstract] [Full Text] [Related]

  • 39. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL.
    Eksp Klin Gastroenterol; 2007 Oct 02; (4):146-52. PubMed ID: 18409502
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.